PHGDH and neoplasm: Of note, it has been shown that primary and metastatic breast cancers differ in their serine biosynthetic requirements for molecular pathways activation, and that this may influence their sensitivity to specific targeted therapies25, while heterogeneous and lower PHGDH expression potentiates tumor dissemination and metastasis formation in breast cancer26.